VBI Vaccines, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: CA91822J2020
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.43 k

Shareholding (Mar 2024)

FII

0.52%

Held by 47 FIIs

DII

95.7%

Held by 4 DIIs

Promoter

0.00%

How big is VBI Vaccines, Inc.?

22-Jun-2025

As of Jan 10, VBI Vaccines, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap company, with net sales of 9.40 million and a net profit of -82.98 million over the last four quarters. The company reported shareholder's funds of 7.53 million and total assets of 86.95 million as of Dec 23.

Market Cap: As of Jan 10, VBI Vaccines, Inc. has a market capitalization of 0.01, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, VBI Vaccines, Inc. reported net sales of 9.40 million and a net profit of -82.98 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of 7.53 million and total assets of 86.95 million.

Read More

Who are in the management team of VBI Vaccines, Inc.?

22-Jun-2025

As of March 2022, the management team of VBI Vaccines, Inc. includes Mr. Steven Gillis (Independent Chairman), Mr. Jeffrey Baxter (CEO), Mr. Christopher McNulty (CFO), and several independent directors: Mr. Damian Braga, Ms. Joanne Cordeiro, Dr. Blaine Mckee, and Dr. Michel Wilde. This team oversees the company's strategic direction and operations.

As of March 2022, the management team of VBI Vaccines, Inc. includes the following individuals:<BR><BR>- Mr. Steven Gillis, Independent Chairman of the Board<BR>- Mr. Jeffrey Baxter, President, Chief Executive Officer, and Director<BR>- Mr. Christopher McNulty, Chief Financial Officer and Head of Business Development, and Director<BR>- Mr. Damian Braga, Independent Director<BR>- Ms. Joanne Cordeiro, Independent Director<BR>- Dr. Blaine Mckee, Independent Director<BR>- Dr. Michel Wilde, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Should I buy, sell or hold VBI Vaccines, Inc.?

22-Jun-2025
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky - Not traded in last 10 days

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 0%, its profits have risen by 51.2%
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-6.76

stock-summary
Return on Equity

1,067.95%

stock-summary
Price to Book

-0.00

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Mar 2024)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-96.0%
0%
-96.0%
6 Months
-99.93%
0%
-99.93%
1 Year
-99.92%
0%
-99.92%
2 Years
-99.89%
0%
-99.89%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

VBI Vaccines, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
21.60%
EBIT Growth (5y)
4.34%
EBIT to Interest (avg)
-14.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-6.76
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
13.73%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-0.78
EV to EBITDA
-0.82
EV to Capital Employed
1.17
EV to Sales
3.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-150.91%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 24 Schemes (3.78%)

Foreign Institutions

Held by 47 Foreign Institutions (0.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2024 is 33.33% vs -86.36% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2024 is 0.00% vs 100.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.20",
          "val2": "0.90",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.30",
          "val2": "-11.90",
          "chgp": "5.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.10",
          "chgp": "-4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.90",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,680.40%",
          "val2": "-14,494.70%",
          "chgp": "481.43%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 690.91% vs 83.33% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 18.09% vs -62.32% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.70",
          "val2": "1.10",
          "chgp": "690.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.30",
          "val2": "-79.80",
          "chgp": "33.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.10",
          "val2": "5.20",
          "chgp": "55.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.60",
          "val2": "-0.20",
          "chgp": "-12,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-92.80",
          "val2": "-113.30",
          "chgp": "18.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,370.80%",
          "val2": "-75,619.20%",
          "chgp": "6,924.84%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQstock-summary
Mar'24
Dec'23
Change(%)
Net Sales
1.20
0.90
33.33%
Operating Profit (PBDIT) excl Other Income
-11.30
-11.90
5.04%
Interest
2.00
2.10
-4.76%
Exceptional Items
0.00
-1.00
100.00%
Consolidate Net Profit
-17.90
-0.00
Operating Profit Margin (Excl OI)
-9,680.40%
-14,494.70%
481.43%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2024 is 33.33% vs -86.36% in Dec 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2024 is 0.00% vs 100.00% in Dec 2023

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
8.70
1.10
690.91%
Operating Profit (PBDIT) excl Other Income
-53.30
-79.80
33.21%
Interest
8.10
5.20
55.77%
Exceptional Items
-24.60
-0.20
-12,200.00%
Consolidate Net Profit
-92.80
-113.30
18.09%
Operating Profit Margin (Excl OI)
-6,370.80%
-75,619.20%
6,924.84%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 690.91% vs 83.33% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 18.09% vs -62.32% in Dec 2022

stock-summaryCompany CV
About VBI Vaccines, Inc. stock-summary
stock-summary
VBI Vaccines, Inc.
Biotechnology
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
Company Coordinates stock-summary
Company Details
222 3rd St Ste 2241 , CAMBRIDGE MA : 02142-1259
stock-summary
Tel: 1 617 83030311 617 8303031
stock-summary
Registrar Details